Pfizer appoints Cecile Guegan as permanent CFO and Executive Vice President

Pfizer has named Cecile Guegan as its permanent Chief Financial Officer (CFO) and Executive Vice President, according to a report carried by Yahoo Finance. The appointment follows what the company described as a competitive search process.

As CFO, Guegan will oversee Pfizer’s finance organization, a role that typically includes financial planning and reporting, capital allocation, and supporting major corporate decisions. The company also positions the CFO role at the executive-vice-president level, indicating that finance leadership is closely tied to overall company strategy.

The announcement comes after the departure of Pfizer’s previous CFO, which Yahoo Finance said prompted the search. Pfizer did not describe, in the information provided here, the timing of the transition or whether Guegan had been serving in an acting or interim finance capacity prior to this permanent appointment.

Pfizer did not provide additional public detail in the Yahoo Finance account about Guegan’s prior responsibilities, the scope of her remit, or any specific near-term financial milestones tied to her appointment. Details that investors typically watch for in CFO changes, such as changes to guidance policy, cost targets, or capital plans, were not laid out in the available text.

Cecile Guegan’s move into a permanent CFO role lands at a time when large drugmakers must balance research and development priorities, manufacturing and supply obligations, and the financial pressure that comes from patent expirations and shifting demand. In that environment, the CFO function is often central to how companies fund pipeline work while maintaining cash flow.